September 27, 2026 · AxonCPT Team · billing, clinical practice, adult ADHD

ADHD Medication Prior Authorization: A PMHNP Checklist

Most ADHD medication prior authorization (PA) requests for adult stimulants turn on the same few questions. Was the diagnosis made against DSM-5 criteria, with impairment in more than one setting? Has the prescriber assessed substance use? Has the patient tried preferred drugs first? Is the dose within plan limits? If your chart already answers those questions in plain language, most PAs become a copy-and-paste job. If it doesn’t, you get denials, peer-to-peer calls, and patients who run out of medication during a shortage.

Prescription bottle with capsules on a table Photo by Alexander Grey on Unsplash

This checklist is written for PMHNPs in small or solo practices, where the prescriber often completes PA forms personally. It is based on current public PA forms and FDA labeling. Every plan is different, so always use the plan’s current form and criteria. For the diagnostic documentation behind a PA, see our guide to ADHD documentation for stimulant prescribing. To add a standardized measure to the record, objective ADHD testing with AxonCPT is one option.

What do stimulant PA forms actually ask?

Here are two current public examples, both Medicaid programs, to show the pattern.

Anthem HealthKeepers Plus (Virginia Medicaid), form dated July 2026 [1]. For adults over 18, the form asks:

  • The diagnoses being treated, with ICD codes
  • Whether the prescriber “use[d] the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and determine[d] that criteria have been met (including documentation of impairment in more than one major setting)”
  • For maintenance requests, whether the prescriber “has regularly evaluated the member for stimulant or other substance use disorder” and treated, consulted, or referred when indicated
  • For non-preferred drugs, which agents were tried and with what outcome
  • A prescriber signature confirming the information “is accurate and verifiable by member records”

Kansas Medical Assistance Program ADHD PA form, revised 05/2026 [2]. For patients 18 and older, it asks:

  • Whether the prescriber is a psychiatrist, and if not, the patient’s documented diagnosis within the previous 365 days
  • Whether the patient has a documented substance use diagnosis within the previous 365 days. If yes, a written peer-to-peer review is required.
  • Whether the dose exceeds the plan’s maximum daily limit. If yes, a peer-to-peer review is required.
  • Clinical rationale for any non-preferred drug

Two points matter for PMHNPs. First, the Kansas form asks whether the prescriber is a psychiatrist, so a non-psychiatrist prescriber must show a documented diagnosis. Second, the Virginia form’s signature line calls the prescriber “the physician,” but it is the prescriber who attests. Either way, a PMHNP’s chart has to be complete enough to answer “yes” truthfully and to back that answer up if records are requested.

Commercial plans and Medicare Part D plans use their own criteria. Some ask for a named rating scale or a specific step-therapy sequence. Read the form before you assume.

The stimulant prior authorization documentation checklist

Keep these items in the chart where you can find them in two minutes:

PA question Chart evidence to have ready Where it usually lives
Diagnosis and ICD-10 code Specific ADHD presentation code, plus comorbid diagnoses Assessment/plan
DSM-5 criteria met Symptom count with examples, onset before 12, symptoms in 2+ settings, impairment, rule-outs [3] Diagnostic evaluation note
Impairment in more than one setting Concrete examples from work, school, home, driving, finances Diagnostic note, informant report
Standardized measure Rating-scale name, score, date; any objective test with date and result Scanned forms, test report
Substance use evaluated SUD history, screening result, PDMP check date Intake note, each follow-up
Misuse risk reassessed Documented at each visit, per labeling [4][5] Follow-up notes
Prior medication trials Drug, dose, duration, and outcome for each trial Medication history
Dose within limits Current dose vs. plan maximum; rationale if higher Plan note
Ongoing benefit (renewals) Change in symptoms and function since baseline, with measures Follow-up notes

Note that FDA labeling for stimulants tells prescribers to assess each patient’s risk of abuse, misuse, and addiction before prescribing and to reassess throughout treatment [4][5]. The same documentation answers the substance-use questions on most PA forms, so doing it once, properly, serves both.

This post intentionally includes no dose-conversion or dose-limit tables. Use the plan’s own published limits and the product labeling.

Why do stimulant PAs get denied?

Common, avoidable reasons:

  1. Diagnosis not supported in the notes. “ADHD, on Adderall from previous provider” without a documented evaluation.
  2. Only one setting documented. The form asks about impairment in more than one setting [1].
  3. Missing step therapy. A non-preferred drug is requested without documented trials of preferred agents [1][2].
  4. Substance use question unanswered or unsupported. Kansas routes any documented SUD diagnosis within 365 days to peer-to-peer review [2].
  5. Dose above plan limit without a written rationale [2].
  6. Incomplete form. Both forms warn that missing information delays or affects the outcome [1][2].

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

What about transferred patients?

Transfers are the hardest PAs for telehealth PMHNPs. A patient arrives on a stimulant from a previous prescriber, sometimes a closed telehealth company, with little documentation. Before renewing:

  • Request prior records, including the original evaluation.
  • Do your own evaluation against DSM-5 criteria. You are the prescriber now, and the attestation on the PA form is yours.
  • Get a current baseline, such as a rating scale and, if you use one, an objective measure. That gives you something to compare against at renewal.
  • Check the PDMP and document the result.

For a step-by-step version of this evaluation, see our adult ADHD intake workflow.

Where objective data helps with prior authorization

We have not seen a public stimulant PA form that requires a continuous performance test, and a CPT does not diagnose ADHD on its own. Objective data can still help in three places:

  • Initial PA: a norm-referenced result is standardized evidence that doesn’t depend on self-report, and it sits beside the rating scales in the “criteria met” documentation.
  • Renewals: a before-and-after comparison is more concrete than “patient reports benefit.” Our post on using objective data in ADHD medication titration covers how to track this.
  • Peer-to-peer reviews: you can point to dated measures when explaining a dose change or a non-preferred drug.

If you plan to bill for the test itself, check payer rules first. Our ADHD testing CPT code guide explains the codes.

How this looks in practice

A PA-ready workflow for a small practice:

  1. Intake: DSM-5-based evaluation, rating scales, substance-use and cardiac history, PDMP check.
  2. Objective baseline: with AxonCPT, you send a link and the patient completes the test from home in about 16 minutes, with no app or login. The report is instant: five metrics against age- and sex-matched norms from a 20,000+ reference dataset. See what the report looks like.
  3. Before prescribing: check the patient’s formulary. Choose a preferred agent where clinically appropriate, or document why not.
  4. Submit the PA: answer from the chart and attach the diagnostic note and measures if the plan accepts attachments.
  5. Follow-up: repeat measures at dose changes, so the renewal packet shows benefit over time.
  6. Keep a PA log: plan, date submitted, outcome, and renewal date.

Frequently asked questions

How long does a stimulant prior authorization last? It varies by plan. The Kansas Medicaid form states that no renewal is required, though a new PA may be needed if dosing exceeds limits [2]. Other plans approve for set periods. Check the approval letter.

Can a PMHNP complete a stimulant PA? Generally, the prescriber of record completes and signs the PA. Some forms ask whether the prescriber is a psychiatrist or specialist and add requirements if not [2]. Your state scope of practice and any collaborative agreement also apply.

Do payers require a specific rating scale? Some commercial plans name one, and many Medicaid forms simply ask whether DSM-5 criteria were met [1][2]. Use a validated scale and record its name, score, and date so you can answer either way.

What if the preferred drug is unavailable because of the shortage? Document the shortage-related failure to fill (pharmacy name, date) and request an exception using the plan’s non-preferred process. Confirm the plan’s shortage policy by phone. For a switching strategy and the current shortage status, see ADHD medication shortage 2026: switching stimulants safely.

Start testing your patients with AxonCPT

Prior authorization is a documentation test, and payers keep asking for the same evidence. AxonCPT adds a standardized, norm-referenced attention measure at baseline and at each dose change, so your chart shows how the diagnosis was supported and whether treatment is working. You get 2 free tests every month, with no card required. Create your free AxonCPT account or learn more at axoncpt.com.

References

  1. Anthem HealthKeepers Plus (Virginia Medicaid). Stimulants/ADHD Medications for Children Less Than FDA Indicated Age and Adults Over 18 Prior Authorization Form. Form VA-BCBS-CD-013656-26, July 2026.
  2. Kansas Department of Health and Environment, Kansas Medical Assistance Program. ADHD Prior Authorization Form. Revised May 2026.
  3. Epstein JN, Loren REA. Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry (London). 2013;3(5):455–458.
  4. U.S. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. May 11, 2023.
  5. U.S. Food and Drug Administration. Adderall XR prescribing information. Revised October 2023.